The increasing rates of resistance among both hospital-and community-acquired bacterial pathogens such as Staphylococcus aureus, coagulase-negative staphylococci, and enterococcci have prompted attempts to discover new antimicrobials with activities against multidrug-resistant gram-positive pathogens (4, 13, 14, 21, 26, 30) . Dalbavancin is a new lipoglycopeptide antibiotic with broad-spectrum activity against multidrug-resistant gram-positive organisms (12, 13, 14, 26, 30, 32) . In addition to enhanced antimicrobial potency, the compound possesses a unique pharmacokinetic (PK) profile that includes an extremely prolonged elimination half-life of more than 1 week (2) . Clinical development of the compound has thus far been successful for the treatment of skin and soft tissue and of catheter-related bloodstream infections (15, 27, 31) . Onceweekly administration of the dosing regimens used in these trials has been shown to produce free-drug trough concentrations exceeding the MIC 90 s of gram-positive pathogens from large surveillance databases.
The current studies were designed to characterize the in vivo pharmacodynamic (PD) characteristics of this new compound. We first examined the impact of the dalbavancin concentration on in vivo antimicrobial killing activity over time. Studies were then performed to determine (i) which PK parameter (the peak concentration in serum [C max / MIC], the area under the concentration-versus-time curve [AUC/MIC], or the duration of time that levels in serum exceed the MIC [T Ͼ MIC]) best predicts the efficacy of dalbavancin and (ii) whether the magnitude of the PK/PD parameter required for efficacy is similar among common gram-positive bacteria, including penicillin-resistant pneumococci and methicillin-resistant S. aureus (MRSA). Lastly, we determined the effect of the infection site on the activity of dalbavancin against both Streptococcus pneumoniae and S. aureus in both the thigh and pneumonia infection models. The results from these studies provide a PD rationale in support of the current clinical dosing regimens. Furthermore, the data provide a starting point for the development of susceptibility breakpoints for this new compound.
MATERIALS AND METHODS
Bacteria, media, and antibiotic. Five strains of Streptococcus pneumoniae with various levels of resistance to penicillin (one penicillin-susceptible S. pneumoniae strain, one penicillin-intermediate S. pneumoniae strain, and three penicillinresistant S. pneumoniae strains) were used. Six strains of Staphylococcus aureus (three methicillin-susceptible S. aureus strains and three MRSA strains) were also used for these experiments. All organisms except S. pneumoniae were grown, subcultured, and quantified in Mueller-Hinton broth (Difco Laboratories, Detroit, MI) and Mueller-Hinton agar (Difco Laboratories). Sheep blood agar plates (Remel, Milwaukee, WI) were used for S. pneumoniae. Dalbavancin was supplied by Vicuron. Penicillin and methicillin were purchased from Sigma.
In vitro susceptibility studies. The MICs and minimal bactericidal concentrations (MBCs) of dalbavancin, penicillin, and methicillin for the various isolates were determined in duplicate on at least two occasions by standard Clinical and Laboratory Standards Institute (formerly NCCLS) microdilution methods (23).
Murine thigh infection model. Animals were maintained in accordance with the criteria of the American Association for Accreditation of Laboratory Animal Care (24) . All animal studies were approved by the Animal Research Committee of the William S. Middleton Memorial VA Hospital. Six-week-old, specificpathogen-free, female ICR/Swiss mice (Harlan Sprague-Dawley, Indianapolis, IN) weighing 23 to 27 g were used for all studies. A neutropenic model was used for all studies, with the exception of a single substudy for determination of the impact of leukocytes. The mice were rendered neutropenic (neutrophils, Ͻ100/ mm 3 ) by injecting them with cyclophosphamide (Mead Johnson Pharmaceuticals, Evansville, IN) intraperitoneally 4 days (150 mg/kg of body weight) and 1 day (100 mg/kg) before the thigh infection study and 100 mg/kg every 48 h (q24h) after the start of infection until the end of the study. Previous studies have shown that this regimen produces neutropenia in this model for more than 7 days (1, 20, 33) . Broth cultures of freshly plated bacteria were grown to logarithmic phase overnight to an absorbance at 580 nm of 0.3 (Spectronic 88; Bausch & Lomb, Rochester, NY). After dilution 1:10 in fresh Mueller-Hinton broth, the bacterial counts of the inoculum ranged from 10 6.6 to 10 7.6 CFU/ml. Thigh infections with each of the isolates were produced by injection of 0.1 ml of inoculum into the thighs of halothane-anesthetized mice 2 h before therapy with dalbavancin. At the end of the study period, the thighs were processed for CFU determination as described previously (1, 20, 33) .
Murine lung infection model. Stationary-phase broth cultures of S. pneumoniae strain ATCC 10813 were obtained by overnight incubation. The cultures were centrifuged at 10,000 ϫ g for 20 min and washed twice in 0.9% saline before being resuspended in saline. Diffuse pneumonia was induced in three mice per treatment regimen by intranasal inoculation of 50 l of an inoculum of 10 8.3 to 10 8.6 CFU/ml. Antimicrobial therapy was initiated 2 h after the infection procedure. Treatment was continued for 72 h. At the end of the study period the animals were euthanized and their lungs were removed, homogenized, diluted, and plated to determine the viable organism burden. The results are expressed as the mean Ϯ standard deviation log 10 CFU/lungs. Drug PKs. Single-dose serum PK studies were performed with thigh-infected mice given intraperitoneal doses (0.2 ml/dose) of dalbavancin (2.5, 5, 10, 20, 40 , and 80 mg/kg). Blood was removed from groups of three mice by retroorbital aspiration and placed into heparinized capillary tubes at 0.5, 1, 2, 4, 6, 24, 48, 72, and 96 h after dosing. The plasma was separated by centrifugation, and dalbavancin plasma concentrations were measured by a microbiologic assay with Bacillus subtilus as the test organism. The lower limit of detection of the assay was 0.10 mg/liter, and the interday variation was less than 6%. Pharmacokinetic constants, including the elimination half-life, AUC, and C max , were calculated by using a noncompartmental model. The half-lives of dalbavancin were determined by linear least-squares regression. The AUC was calculated from the mean concentrations by use of the trapezoidal rule. The AUC was estimated at 24, 36, 48, 72, and 96 h and was extrapolated to infinity. An accumulation factor was considered for the shorter-dosing-interval studies (q12h and q24h).
Protein binding. The impact of serum protein binding was assessed by examining the impact of 95% mouse serum on the activity of dalbavancin in vitro (7) . The dalbavancin MICs for S. aureus ATCC 25923 and S. aureus MRSA were determined in broth, heat-treated (100°C for 30 min) 95% mouse serum, and 95% serum ultrafiltrate by using arithmetic dilutions of 0.02 mg/liter per tube. A reduced potency (higher MIC) in serum was presumed due to drug binding to serum protein. The difference in potency was used to estimate the percentage of protein binding by the following equation: (MIC in 95% serum Ϫ MIC in serum ultrafiltrate)/MIC in 95% serum. Previous studies have demonstrated that these staphylococcal isolates grow well in the presence of mouse serum. Other methodologies by filtration and dialysis were attempted (7, 18 , and 96 h) and two untreated control mice (sampled at 0, 1, 2, 4, 6, 24, and 48 h) were each killed at sampling intervals ranging from 0.5 to 24 h. The thighs were removed at each time point and immediately processed for CFU determination. Data are expressed as the mean Ϯ standard deviation log 10 CFU/thigh.
(ii) PK/PD index determination. Neutropenic mice were infected with a strain of either penicillin-susceptible S. pneumoniae ATCC 10813 or MRSA strain ATCC 29213. Treatment with dalbavancin was initiated 2 h after infection. Groups of two mice were treated for 6 days with 20 different dosing regimens by using twofold-increasing total doses divided into 2, 4, 6, or 12 doses (q72h, q36h, q24h, and q2h, respectively). The total doses of dalbavancin ranged from 3.8 to 60 mg/kg/6 days for S. pneumoniae and 30 to 480 mg/kg/6 days for S. aureus. The drug doses were administered intraperitoneally in 0.2-ml volumes. The mice were killed after 144 h of therapy, and the thighs were removed and processed for CFU determination. Untreated control mice were killed just before treatment and after 48 h.
(iii) PK/PD index magnitude studies. Similar dosing studies with six fourfoldincreasing dalbavancin doses administered q24h or q72h were used to treat thigh-infected neutropenic animals with five strains of S. pneumoniae (one penicillin-susceptible strain, one penicillin-intermediate strain, three penicillin-resistant strains) and six strains of S. aureus (three methicillin-susceptible strains and three MRSA strains). The dalbavancin MICs for the organisms studied varied 30-fold. The animals were treated for a period of 144 h. The total dose of dalbavancin used in these studies varied from 0.625 to 960 mg/kg/6 days.
(iv) Impact of host infection site and immune status. Two additional dosing studies were designed to determine the impacts of the infection site and host immune state. In the first of those studies, the in vivo efficacies of dalbavancin in the pneumonia and thigh infection models by using S. pneumoniae strain ATCC 10813 were compared. In the second of those studies, the activity of dalbavancin in neutropenic mice was compared to that in nonneutropenic mice infected with S. pneumoniae ATCC 10813 in the thigh infection model. Data analysis. The results of these studies were analyzed by using the sigmoid dose-effect model (5) . The model, as follows, is derived from the Hill equation:
, where E is the effect or, in this case, the log 10 change in CFU per thigh or lung between treated mice and untreated controls after the 144-h period of study; E max is the maximum effect; D is the 144-h total dose; ED 50 is the dose required to achieve 50% of E max ; and N is the slope of the dose-effect curve. The indices E max , ED 50 , and N were calculated by using nonlinear least-squares regression. The correlation between efficacy and each of the three PK/PD indices studied (T Ͼ MIC, AUC/MIC, C max /MIC) was determined by nonlinear least-squares multivariate regression (Sigma Stat; Jandel Scientific Software, San Rafael, CA). The coefficient of determination (R 2 ) was used to estimate the variance that could be due to regression with each of the PK/PD indices. We used the 72-h static dose as well as the doses necessary to achieve both a 1-log 10 reduction and a 2-log 10 reduction in colony counts compared to the numbers at the start of therapy to compare the impact of the dosing interval on treatment efficacy. If these dose values remained similar among each of the dosing intervals, this would suggest that AUC/MIC is the predictive index. If the dose values increased as the dosing interval was lengthened, this would suggest that T Ͼ MIC is the predictive parameter. Lastly, if the dose value decreased as the dosing interval was increased, this would suggest that C max /MIC is the pharmacodynamically important index.
To allow a comparison of the potency of dalbavancin against a variety of organisms, we used similar dosing endpoints (72-h static dose and the doses required to achieve a 1-log 10 reduction and a 2-log 10 reduction in colony counts). The magnitude of the PK/PD index associated with each endpoint dose was calculated from the following equation: log 10 D ϭ log 10 [E/(E max Ϫ E)]/(N ϩ log 10 ED 50 ), where E is the control growth for the static dose (D), E is the control growth Ϫ 1 log unit for a D of 1-log killing, and E is the control Ϫ 2 log units for a D of 2-log killing. The significance of differences among the various dosing endpoints was determined by using analysis of variance. Fig. 1 . Peak levels were observed by 4 h. Dalbavancin exhibited linear pharmacokinetics from 2.5 to 40 mg/kg. The half-life was prolonged and varied from 9.6 to 13.1 h. The level of protein binding of dalbavancin in pooled 95% serum from infected mice was 98.4% (Table 2) .
RESULTS

Study organisms and dalbavancin MICs. The study organisms and the MICs and MBCs of dalbavancin are listed in
In vivo time-kill study. The effect of single doses of dalbavancin on the in vivo killing of a strain of S. pneumoniae and a strain of S. aureus over time are shown in Fig. 2 . At the start of therapy mice had 10 7.6 CFU/thigh of either organism. Both organisms grew nearly 2 log 10 units over the first 24 h in the thighs of untreated control mice. The two lowest dose levels of dalbavancin were relatively ineffective at reducing or suppressing organism growth. The extent and the rate of killing of the pneumococcal isolate were greater than those of the staphylococcal strain. Only the two highest doses of dalbavancin resulted in the killing of S. aureus. Three of the five dose levels used in study against S. pneumoniae reduced the burden of organisms nearly 4 log 10 units in the thighs of infected mice. Organism reduction continued over the first 48 h of in vivo exposure to S. pneumoniae and over the entire 96-h period for S. aureus. Additional killing may have been produced in the S. pneumoniae model system; however, the reductions were at the lower limit of detection by 48 h. We did not observe appreciable organism recovery or regrowth over the 96-h period of observation.
Dosing regimen studies. Figure 3 illustrates the dalbavancin dose-response curves for the different dosing intervals against the strains of S. pneumoniae and S. aureus studied in the thighs of neutropenic mice. Each point represents the mean for four thighs. The dotted lines represent the number of bacteria at the start of therapy. In general, increasing the dosing interval resulted in a shift of the dose-response curves to the left, indicating greater efficacy with the regimens for which large doses were administered infrequently. Similar to the singledose time-kill studies, against S. pneumoniae, we observed more rapid and extensive killing than we did for S. aureus. However, maximal reductions with the largest most infrequently administered regimens in the S. aureus model still resulted in nearly a 3-log 10 -unit reduction in the thigh organism burden compared to that at the start of therapy. Each of the dose-response curves was also mathematically characterized by using a maximum-effect model. This methodology uses the Hill equation to estimate by nonlinear regression E max , the ED 50 , and the slope of the dose-response relationship (1, 5) . From these parameters we calculated the dose required to produce a net bacteriostatic effect over the 144-h treatment period as well as the doses necessary to produce a 1-and 2-log reductions in the organism burden. The static dose and the doses associated with 1-and 2-log killing for each of the drug-organism combinations and the various dosing regimens are shown in Table 3 .
Increasing the frequency of the dosage regimen from 12 to 36 h in study against S. pneumoniae did not result in appreciable changes in the doses associated with the three microbiologic endpoints. However, efficacy with the 72-h dosing interval required less drug. Statistical comparison of these differences were significant (P Ͻ 0.05) among all of the regimens (q12h versus q24h, q12h versus q36h, q12h versus q72h, q24h versus q72h, and q36h versus q72h), with the exception of the q24h and q36h intervals. A similar relationship was observed in the study against S. aureus. However, there was more variability in the S. aureus data set. The only regimens for which the differences were statistically significant for S. aureus were the q12h interval versus the other more extended intervals. The only dosing regimens that produced 1-and 2-log killing of S. aureus were the q36h and q72h intervals. Both visual inspection of the dose-response curves in Fig. 2 and these statistical comparisons suggest that large infrequent dosing of dalbavancin was most effective in this model against both bacterial species. This pattern of activity would suggest that either the 24-h AUC/MIC or the C max /MIC PD index would be the most important for describing the activity of this lipoglycopeptide (5) .
PD parameters correlating with efficacy. Subsequent analysis of the dose-response data examined the impact of each of on February 27, 2014 by PENN STATE UNIV http://aac.asm.org/ the three PD indices by relating the number of bacteria in thigh at the end of 144 h of therapy with (i) the C max /MIC ratio, (ii) the 24-h AUC/MIC ratio, and (iii) the T Ͼ MIC for each of the dosage regimens studied. The PK/PD index values for those doses not specifically studied were extrapolated from the values of the nearest doses studied. For the AUC/MIC index, we calculated the predicted AUC over time as opposed to the AUC to infinity for all regimens. The dalbavancin accumulation for C max was considered in these calculations for the shorter dosing intervals. The relationship between the log 10 numbers of CFU per thigh and the C max /MIC ratio, the 24-h AUC/MIC ratio, and the T Ͼ MIC are illustrated in Fig. 4 for S. pneumoniae and S. aureus. Each point represents the mean for four thighs. For both organisms a strong correlation was observed with the 24-h AUC/MIC and the C max /MIC ratios. Regression of the data with the 24-h AUC/MIC ratio resulted in the strongest correlation for S. aureus (R 2 ϭ 77% for the 24-h AUC/MIC and 57% for the C max /MIC). However, for S. pneumoniae the C max regression fit was the strongest (R 2 ϭ 78% for the 24-h AUC/MIC and 90% for the C max /MIC). Regression of the dose-response data with the T Ͼ MIC parameter resulted in a poor fit of the data, with R 2 values below 10%.
PK/PD index magnitude or target. Both the concentrationdependent indices were important predictors of the in vivo efficacy of dalbavancin. For comparison of the index magnitude among strains with various MICs, we chose to examine the 24-h AUC/MIC index due to the extremely prolonged elimination half-life in humans. To determine if the 24-h AUC/ MIC (by the use of free drug values) required for a static effect was similar for multiple pathogens, we studied the activities of the q24h and q72h dosing regimens of dalbavancin against five strains of S. pneumoniae and six strains of S. aureus. The dose-response curves for dalbavancin against these various strains are shown in Fig. 5 . The growth curves of the five pneumococcal and staphylococcal strains for the thighs of the control animals were similar. At the start of therapy the mice had 6.9 Ϯ 0.21 log 10 CFU/thigh of pneumococci (range, 6.6 to 7.2 log 10 CFU/thigh of pneumococci). The organism burdens at the start of therapy were similar for the staphylococci and ranged from 6.3 to 7.3 log 10 CFU/thigh. The organisms grew to 2.1 Ϯ 0.5 log 10 CFU/thigh in the control mice. In general, the shapes of the dose-response curves were similar for all strains. The location of the dose-response curve was related to the MIC of the organism. However, the dose-response curves for the pneumococcal organisms were shifted slightly to the left. This curve shift suggests that less drug was necessary for the drug to have an effect against pneumococci than against staphylococci. The static dose, the doses associated with 1-log and 2-log killing, and the associated free-drug 24-h AUC/MIC are shown in Table 4 . The extent of bacterial killing was relatively similar for most strains. All strains exhibited more than a 4-log 10 drop in the numbers of CFU following dalbavancin therapy over the 6-day study compared to the numbers of CFU for the untreated controls.
For the dalbavancin regimens with q24h dosing, the freedrug 24-h AUC/MICs associated with a static effect against S. pneumoniae and S. aureus were 18 Ϯ 7 and 265 Ϯ 143, respectively. Therapy against pneumococci, based upon the 24-h AUC/MIC, required 2.1-to 6.4-fold less drug, as suggested by the dose-response curves, compared to the amount required for S. aureus. When the drug exposure for the S. aureus strains was considered relative to the MBC, the AUC/MICs were lower, yet they were still larger than those for S. pneumoniae. The dose-response curves with both species were relatively steep, and the 24-h AUC/MICs associated with 1-and 2-log killing were not appreciably higher than that associated with a net static effect. For the regimens that used less frequent dosing (q72h), the free-drug 24-h AUC/MICs associated with a static effect against S. pneumoniae and S. aureus were 7.2 Ϯ 4.52 and 160 Ϯ 67, respectively. The PK/PD magnitudes necessary to achieve the three in vivo microbiologic endpoints (static dose and the doses associated with 1-and 2-log killing) were lower for the more widely spaced dosing regimens. When dalbavancin was dosed every 72 h, the 24-h AUC/MICs associated with the various endpoints were 1.3-to 2.4-fold lower than those found when the drug was dosed q24h. Penicillin resistance in S. pneumoniae and methicillin resistance in S. aureus did not affect the 24-h AUC/MIC required for dalbavancin efficacy. Impacts of neutrophils and infection site on activity of dalbavancin. To determine the effects of neutrophils on the activity of dalbavancin, we compared the dose-response curves with dosing of the drug q24h in both healthy (nonneutropenic) and neutropenic mice infected with S. pneumoniae. The static dose and the doses associated with 1-and 2-log killing were calculated from the parameters estimated by nonlinear regression by using the Hill equation, as described above. The doses (mg/kg/6 days) required to achieve these endpoints in both healthy and neutropenic mice are shown in Table 5 . The presence of neutrophils resulted in 1.7-to 2.1-fold reductions in the doses necessary for efficacy. However, these differences were not statistically significant.
To determine the impact of the infection site on the activity of dalbavancin, we compared the dose-response curves with the q24h dosing of the drug in both the thigh and the lung infection models (Fig. 6) . The dose-response curves in the two models with S. pneumoniae were nearly identical. These data suggest that the PD target was independent of infection site (soft tissue sepsis and pneumonia).
DISCUSSION
A variety of in vitro and in vivo studies have demonstrated that the killing activities of glycopeptide antibiotics, such as vancomycin and teicoplanin, are not enhanced by exposure to drug concentrations far exceeding the MIC (3, 6, 8, 9, 10, 11, 16, 17, 19, 25, 29) . However, they have been shown to produce moderately long in vitro postantibiotic effects. The in vivo efficacies of antimicrobial drugs exhibiting these time course characteristics are most often best described by the 24-h AUC/ MIC PD parameter. Several dose fractionation studies with vancomycin suggest that the data fit best when they are regressed with either the AUC/MIC or the C max /MIC parameter. However, a few studies report contradictory conclusions, in which the T Ͼ MIC was believed to better predict treatment results. The current studies have characterized the in vivo PD activity of dalbavancin against a variety of pathogens. This lipoglycopeptide demonstrated in vivo dose-dependent bactericidal activity against both S. pneumoniae and S. aureus. Regression of the dose fractionation studies with each of the PK/PD parameters demonstrated the importance of both the 24-h AUC/MIC and the C max /MIC. Correlation of the results of the dose fractionation experiments with the T Ͼ MIC parameter resulted in a very poor data fit. These dose-response relationships clearly support the use of large infrequent doses to optimize in vivo treatment efficacy.
The next logical PD-related question is to ask what drug exposure is necessary for treatment effect. More simply put, how much drug relative to the MIC needs to be given for efficacy? A study with vancomycin in the neutropenic murine thigh infection model also reported that AUC/MICs ranging from 80 to 460 were needed to produce 50% of maximum killing over a 24-h treatment period (9) . Analysis of the treatment efficacy of vancomycin in patients with ventilator-associated pneumonia caused by S. aureus reported that a similar range of exposure (mean 24-h AUC/MICs of 345 for clinical outcome and 850 for microbiologic cure) was associated with positive patient outcomes (22) . These exposure-response relationships suggest that the glycopeptide concentrations associated with in vivo efficacy are larger than those needed for efficacy in vitro. For example, averaging of 1ϫ the MIC over 24 h in vitro would result in a 24-h AUC/MIC ratio of 24. Even if free-drug concentrations are considered, for vancomycin against S. aureus, optimal outcomes in vivo are observed when concentrations exceed the in vitro MIC by a factor of four to eight over the treatment period (corresponding to 24-h AUC/ MICs up to several hundred). The dalbavancin in vivo exposures associated with a net static effect for the S. aureus isolates examined in the current study were similar to those values for vancomycin with 24-h AUC/MICs. Interestingly, the dose-response curves were relatively steep, and the exposures necessary to produce significant organism killing (1-and 2-log 10 reductions) were not much larger than those associated with a net static effect (less than twofold). The dose-response relationships were fairly similar among the five S. aureus strains examined, and methicillin resistance, not surprisingly, had no impact on the dalbavancin PD target associated with efficacy.
The dose-response curves in studies with each of the five S. pneumoniae isolates was shifted to the left compared to those A number of host, organism, and drug factors have been theorized to affect the PD target necessary for efficacy. For most antimicrobials, in vivo PD studies have demonstrated that these variables do not markedly impact the PD target. However, there are a few situations where experimental observations suggest significant differences. For example, with drugs from the fluoroquinolone class, the presence of neutrophils can enhance antimicrobial activity by up to a factor of four to six (1, 5) . Another host variable of demonstrated importance for some antimicrobials is the ability to penetrate into the epithelial lining fluid of the lung. Some antimicrobial compounds, such as the macrolides and the quinolones, achieve relatively high concentrations in this tissue space compared to those achieved in serum. Conversely, some molecules such as vancomycin do not attain high concentrations in the epithelial lining fluid relative to those concentrations observed in serum and other interstitial tissue spaces. In the current investigations we examined the impacts of two host variables on the in vivo efficacy of dalbavancin. In the first study we compared the efficacy of dalbavancin against a strain of S. pneumoniae in both neutropenic and nonneutropenic mice by using the thigh infection model. In the nonneutropenic model, the dose-response curve was slightly shifted to the left, suggesting that less drug was needed when the mice were healthy than when the mice were immunocompromised. For each microbial endpoint examined (static dose and the doses associated with 1-and 2-log 10 killing), nearly twofold less dalbavancin was required. However, these differences did not reach statistical significance. We next compared the in vivo activity of dalbavancin against S. pneumoniae in both the thigh infection and the pneumonia models. The dose-response relationship was nearly identical for both infection sites, suggesting that dalbavancin achieves concentrations in the mouse lung that are similar to those achieved in serum and soft tissue. However, for some compounds, studies have suggested that penetration into mouse epithelial lining fluid does not always correlate with the kinetics in this tissue space in humans (W. A. Craig, unpublished data). Thus, it will be important to explore the kinetics in epithelial lining fluid and treatment efficacy for dalbavancin in patients.
In summary, the current studies demonstrate that dalbavancin has dose-dependent in vivo efficacy against pneumococci and staphylococci, independent of beta-lactam resistance, the presence of host neutrophils, or the infection site. The 24-h AUC/MIC parameter was very highly associated with in vivo dalbavancin activity. These PD characteristics support the infrequent administration of large doses. Against pneumococci, PD target studies suggest that achieving concentrations near the in vitro MIC over the dosing period produces optimal efficacy (i.e., a free-drug 24-h AUC/MIC of nearly 25ϫ or 1ϫ the MIC for 24 h). A larger drug exposure was needed for similar efficacy against S. aureus. The 24-h AUC/MIC target associated with efficacy against this bacterial species was in the range of 100 to 300. These observations are similar to those observed for other glycopeptides and S. aureus (8) .
Human PK studies with dalbavancin demonstrate that is has an extremely long half-life and serum concentrations that exceed the MIC 90 for target gram-positive pathogens more than 1 week following the administration of a single dose (2) . If one considers the PD targets identified in the current in vivo models, current dalbavancin dosing regimens would exceed the free-drug 24-h AUC/MICs for both streptococci and staphylococci. For example, the dalbavancin serum exposure following the administration of a single dose of 1 g produces a free-drug AUC of more than 1,500 mg ⅐ h/liter. Studies have also examined the trough free-drug concentrations at the end of 1-and 2-week treatment periods; the values exceed 2 g/ml. When these kinetic values are considered relative to MIC 90 values of Ͻ0.12 mg/liter, one would anticipate more than adequate PD target attainment.
